Pharmosa Biopharm Inc. (TPEX: 6875)

Market Cap	8.18B
Revenue (ttm)	324.12M
Net Income (ttm)	27.78M
Shares Out	129.02M
EPS (ttm)	0.23
PE Ratio	276.61
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	326,068
Open	66.40
Previous Close	66.50
Day's Range	62.90 - 66.80
52-Week Range	48.25 - 125.50
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Pharmosa Biopharm

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It is developing L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei Ci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6875